Percutaneous Nephroscopic Treatment of Parapelvic Cysts

Sponsor

Xiangya Hospital of Central South University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05504512

Collaborator

(none)

Enrollment

Location

Anticipated Duration (Months)

2.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Background of the project: The surgical treatment of parapelvic cysts is currently less researched and there is no gold standard for surgery. Previously, in percutaneous nephrolithotomy, we found that fenestration and fenestration drainage in the simultaneous treatment of pararenal pelvis cysts under nephroscopic nephroscopic surgery has clear curative effect, less trauma, and quicker recovery.

Objective: To clarify the safety, efficacy and long-term efficacy of percutaneous nephroscopy in the treatment of parapelvic cysts.

Nature: Retrospective case cohort study. Basic research process: Retrospective collection of cases in our hospital who underwent percutaneous nephroscopy for the treatment of parapelvic cysts, and comparison of preoperative and postoperative cyst size changes and long-term efficacy.

Condition or Disease	Intervention/Treatment	Phase
Kidney Stone Parapelvic Cyst Kidney Diseases Recurrence	Other: No intervention

Study Design

Study Type:

Observational

Anticipated Enrollment :

40 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

Feasible Surgical Treatment of Peripelvic Cyst by Percutaneous Nephroscopy

Anticipated Study Start Date :

Sep 1, 2022

Anticipated Primary Completion Date :

Nov 30, 2023

Anticipated Study Completion Date :

Dec 31, 2023

Arms and Interventions

Arm	Intervention/Treatment
Parapelvic cyst	Other: No intervention No intervention

Arm

Intervention/Treatment

Parapelvic cyst

Other: No intervention

No intervention

Outcome Measures

Primary Outcome Measures

cyst size [At least 1 year after percutaneous nephroscopy for parapelvic cysts]
Cyst maximum plane diameter

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age 18 or older； Has undergone percutaneous nephroscopic surgery for parapelvic cysts； Ability to receive study follow-up.

Exclusion Criteria:

Patient refuses or is unable to give consent

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Xiangya hospital of central south university	Changsha	Hunan	China

Sponsors and Collaborators

Xiangya Hospital of Central South University

Investigators

Principal Investigator: Yu Cui, M.D., Xiangya Hospital of Central South University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Xiangya Hospital of Central South University

ClinicalTrials.gov Identifier:

NCT05504512

Other Study ID Numbers:

202208180

First Posted:

Aug 17, 2022

Last Update Posted:

Aug 17, 2022

Last Verified:

Aug 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Undecided

Plan to Share IPD:

Undecided

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Xiangya Hospital of Central South University

Parapelvic Cyst

Recurrence

Kidney Diseases

Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 17, 2022